AbbVie Inc. v. Amneal Pharmaceuticals, LLC
1:16-cv-00398
Overview
Parties
Defendant
Amneal Pharmaceuticals of New York, LLC Operating Company
Represented By
2 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Amneal Pharmaceuticals, LLC Operating Company
Represented By
2 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
AbbVie Inc. Operating Company
Represented By
3 Attorneys ListedPolsinelli PC
222 Delaware Avenue, Suite 1101, Wilmington, DE 19801
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
AbbVie Inc. v. Aurobindo Pharma Limited
AbbVie Inc. v. Aurobindo Pharma Limited
AbbVie Inc. v. Roxane Laboratories Inc.
AbbVie Inc. v. Mylan Pharmaceuticals Inc.
AbbVie Inc. v. Roxane Laboratories Inc.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7148359
Polymorph of a pharmaceutical
|
Filed: 2005-05-04
Issued: 2006-12-12
|
Expired (Term Ended)
Expires: 2025-05-04
|
|
|
US7364752
Solid dispersion pharamaceutical formulations
|
Filed: 2000-11-10
Issued: 2008-04-29
|
Expired (Term Ended)
+688d PTA
Expires: 2022-09-29
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).